About relatlimab + nivolumab histidine
PD-1 and LAG-3 immune checkpoint inhibitors
Used for
- Treats certain adults and children aged 12 years or older with unresectable or metastatic melanoma.
Usual adult dose
480 mg relatlimab plus 160 mg nivolumab by intravenous infusion every four weeks, until progression or unacceptable toxicity.
Usual dose in children
For patients aged 12 years or older weighing at least 40 kg, the adult dose is used. Not indicated for younger or lighter patients.
Common side effects
- Muscle and joint pain, tiredness, rash, itching
- Diarrhea, nausea, reduced appetite
- Cough, shortness of breath, fever
- Immune-related inflammation affecting organs such as the lungs, liver, bowel, or thyroid
Important warnings
- Immune reactions can be severe or fatal and may affect any organ, even after treatment ends.
- Seek urgent assessment for breathing difficulty, severe diarrhea, jaundice, unusual weakness, or vision changes.
- Infusion reactions can occur; treatment may be paused or stopped.
- Monitor for immune-related effects during treatment and after the final dose.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for at least five months after the last dose.
Breastfeeding
Do not breastfeed during treatment or for at least five months after the last dose.
Interactions
- Systemic corticosteroids or other immune-suppressing medicines may affect treatment; use requires clinician review.
- Other medicines can complicate recognition or treatment of immune-related side effects.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.